

(43) International Publication Date  
14 July 2011 (14.07.2011)(10) International Publication Number  
**WO 2011/085033 A2**

## (51) International Patent Classification:

C07C 323/59 (2006.01) A61P 11/06 (2006.01)  
A61K 31/196 (2006.01) A61P 29/00 (2006.01)  
A61K 31/10 (2006.01)

## (21) International Application Number:

PCT/US2011/020264

## (22) International Filing Date:

5 January 2011 (05.01.2011)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

61/292,807 6 January 2010 (06.01.2010) US

(71) Applicant (for all designated States except US): **AMIRA PHARMACEUTICALS, INC.**; 9535 Waples Street, Suite 100, San Diego, CA 92121 (US).

## (72) Inventors; and

(75) Inventors/Applicants (for US only): **BRITTAIN, Jason, Edward**; 1580 Chiswick Court, El Cajon, CA 92020 (US). **KING, Christopher, David**; 7396 Escallonia Court, Carlsbad, CA 92011 (US). **STEARNS, Brian, Andrew**; 157 Beechtree Drive, Encinitas, CA 92024 (US).

(74) Agent: **HOSTETLER, Michael, J.**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

[Continued on next page]

(54) Title: DP<sub>2</sub> ANTAGONIST AND USES THEREOF

FIG. 1

XRPD of amorphous Compound 2



(57) Abstract: Described herein is the DP<sub>2</sub> antagonist 2-(3-(2-((tert-butylthio)methyl)-4-(2,2-dimethylpropionylamino)phenoxy)-4-methoxyphenyl)acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP<sub>2</sub> antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP<sub>2</sub> antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D<sub>2</sub>-dependent or prostaglandin D<sub>2</sub>-mediated diseases or conditions.



---

**Published:**

- *without international search report and to be republished  
upon receipt of that report (Rule 48.2(g))*